Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy

Haraoui, 2009, Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action, Semin Arthritis Rheum, 39, 176, 10.1016/j.semarthrit.2008.06.004 Benucci, 2012, Tumor necrosis factors blocking agents: analogies and differences, Acta Biomed, 83, 72 Smith, 2009, Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease, J Exp Med, 206, 1883, 10.1084/jem.20091233 Oh, 2005, Development of Crohn's disease in a patient taking etanercept, J Rheumatol, 32, 752 Fouache, 2009, Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study, Rheumatology (Oxford), 48, 761, 10.1093/rheumatology/kep083 Dallocchio, 2010, Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study, Rheumatology (Oxford), 49, 1694, 10.1093/rheumatology/keq136 Braun, 2007, Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents, Arthritis Rheum, 57, 639, 10.1002/art.22669 Oikonomou, 2010, Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence?, J Gastrointestin Liver Dis, 19, 342 Khirfan, 2014, Colitis associated with biological agents, Dig Dis Sci, 59, 1112, 10.1007/s10620-014-3147-x Toussirot, 2012, Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series, Joint Bone Spine, 79, 457, 10.1016/j.jbspin.2011.10.001 Sandborn, 2001, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, 1088, 10.1053/gast.2001.28674 Song, 2008, New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept, J Rheumatol, 35, 532 Silverberg, 2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, 5A, 10.1155/2005/269076 Georgopoulos, 1996, Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice, J Inflamm, 46, 86 Agency EM. Etanercept-Enbrel Product information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf [accessed 24.02.15] Scallon, 2002, Binding and functional comparisons of two types of tumor necrosis factor antagonists, J Pharmacol Exp Ther, 301, 418, 10.1124/jpet.301.2.418 Bawany, 2014, Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature, Am J Ther, 21, e26, 10.1097/MJT.0b013e31825e6089 Fiehn, 2011, Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis, Arthritis Rheum, 63, 3640, 10.1002/art.30546 Fernandez Salazar, 2013, Crohn's disease diagnosis during adalimumab treatment, Scand J Gastroenterol, 48, 254, 10.3109/00365521.2012.733956 Robinson, 2006, Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002, Curr Med Res Opin, 22, 989, 10.1185/030079906X104641 García-Vicuña, 2015, Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: a study in the AQUILES cohort, Reumatol Clin, 12, 22, 10.1016/j.reuma.2015.01.002 Barthel, 2015, Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics, J Rheumatol, 42, 2160, 10.3899/jrheum.140472